Key Takeaway: Jazz Pharmaceuticals has announced that it will report its second quarter financial results on August 3, 2026. The report will be released after the U.S. financial markets close, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register in advance for the call and access a replay via the company's website.
Price reaction · baseline $243.47 (2026-07-20 close) · hit after-hours · clean, no other JAZZ news in the window
day 0 close · peak
+4.4%
Market Sentiment Analysis
POSITIVE FACTORS
Jazz Pharmaceuticals is set to report its financial results, indicating ongoing business activity.
The company is committed to developing life-changing medicines for patients with rare diseases.
Management will provide a business and financial update, showcasing transparency.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
2.1%
average across 14 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2
Full Press Release Details
DUBLIN,July 20, 2026/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update.
Interested parties may register for the call in advancehereor via the Investors section of the Jazz Pharmaceuticals website atwww.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.